Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage

Not Applicable

Completed

Conditions: Cancer

Interventions: Dietary Supplement: 1 tablet composed of antioxidants and minerals

First Posted Date: 2009-12-23

Last Posted Date: 2013-03-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01038024

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

Not Applicable

Withdrawn

Conditions: Esophageal Neoplasm

Interventions: Drug: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)

First Posted Date: 2009-12-18

Last Posted Date: 2012-07-02

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01035437

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Drug: LBH589

First Posted Date: 2009-12-15

Last Posted Date: 2017-01-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01032148

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen

First Posted Date: 2009-12-08

Last Posted Date: 2017-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 59

Registration Number: NCT01027416

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Phase 1

Terminated

Conditions: Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis

Interventions: Drug: Arsenic Trioxide
Dietary Supplement: Ascorbic Acid
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2009-11-17

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01014546

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Phase 1

Completed

Conditions: Metastatic Malignant Neoplasm in the Lung
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: Cisplatin
Other: Pharmacological Study

First Posted Date: 2009-11-17

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01014598

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Phase 2

Completed

Conditions: Cholangiocarcinoma

Interventions: Drug: Gemcitabine, Capecitabine and Bevacizumab

First Posted Date: 2009-11-04

Last Posted Date: 2017-03-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01007552

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

Guided Biopsy for Mapping Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Prostatectomy

First Posted Date: 2009-11-03

Last Posted Date: 2014-02-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01007214

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: cetuximab with irinotecan

First Posted Date: 2009-10-29

Last Posted Date: 2015-10-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01004159

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Clofarabine

First Posted Date: 2009-10-29

Last Posted Date: 2016-06-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01003678

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy